A detailed history of Israel Englander (Millennium Management LLC) transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Millennium Management LLC holds 501,690 shares of ASND stock, worth $65.1 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
501,690
Previous 473,449 5.96%
Holding current value
$65.1 Million
Previous $64.6 Million 16.04%
% of portfolio
0.04%
Previous 0.03%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$113.0 - $153.43 $3.19 Million - $4.33 Million
28,241 Added 5.96%
501,690 $74.9 Million
Q2 2024

Aug 14, 2024

BUY
$121.07 - $153.67 $13.5 Million - $17.1 Million
111,389 Added 30.77%
473,449 $64.6 Million
Q1 2024

May 15, 2024

BUY
$123.45 - $159.4 $41.9 Million - $54.1 Million
339,669 Added 1516.99%
362,060 $54.7 Million
Q4 2023

Feb 14, 2024

BUY
$86.1 - $127.36 $1.93 Million - $2.85 Million
22,391 New
22,391 $2.82 Million
Q4 2022

Feb 14, 2023

SELL
$99.42 - $131.97 $1.89 Million - $2.51 Million
-19,009 Reduced 71.64%
7,524 $919,000
Q3 2022

Nov 14, 2022

SELL
$84.03 - $110.23 $3.23 Million - $4.23 Million
-38,390 Reduced 59.13%
26,533 $2.74 Million
Q2 2022

Aug 15, 2022

SELL
$78.08 - $117.61 $7.2 Million - $10.8 Million
-92,241 Reduced 58.69%
64,923 $6.04 Million
Q1 2022

May 16, 2022

BUY
$102.18 - $135.75 $3.23 Million - $4.29 Million
31,568 Added 25.13%
157,164 $18.4 Million
Q4 2021

Feb 14, 2022

SELL
$127.1 - $169.66 $7.47 Million - $9.97 Million
-58,788 Reduced 31.88%
125,596 $16.9 Million
Q3 2021

Nov 15, 2021

BUY
$112.67 - $176.92 $19.8 Million - $31.1 Million
175,906 Added 2074.85%
184,384 $29.4 Million
Q2 2021

Aug 16, 2021

SELL
$121.62 - $145.29 $7.36 Million - $8.79 Million
-60,532 Reduced 87.71%
8,478 $1.12 Million
Q1 2021

May 17, 2021

SELL
$124.92 - $173.33 $2.12 Million - $2.94 Million
-16,981 Reduced 19.75%
69,010 $8.89 Million
Q4 2020

Feb 16, 2021

SELL
$151.2 - $182.76 $5.34 Million - $6.46 Million
-35,347 Reduced 29.13%
85,991 $14.3 Million
Q3 2020

Nov 16, 2020

SELL
$134.29 - $154.32 $11.6 Million - $13.3 Million
-86,280 Reduced 41.56%
121,338 $18.7 Million
Q2 2020

Aug 14, 2020

SELL
$110.87 - $156.01 $6.92 Million - $9.74 Million
-62,459 Reduced 23.13%
207,618 $30.7 Million
Q1 2020

May 14, 2020

SELL
$97.01 - $145.11 $21.2 Million - $31.7 Million
-218,685 Reduced 44.74%
270,077 $30.4 Million
Q4 2019

Feb 14, 2020

SELL
$91.45 - $139.12 $47.7 Million - $72.6 Million
-521,581 Reduced 51.62%
488,762 $68 Million
Q3 2019

Nov 14, 2019

SELL
$95.8 - $118.9 $10.2 Million - $12.7 Million
-106,611 Reduced 9.54%
1,010,343 $97.3 Million
Q2 2019

Aug 15, 2019

BUY
$107.11 - $132.09 $117 Million - $144 Million
1,089,778 Added 4010.08%
1,116,954 $129 Million
Q2 2019

Aug 14, 2019

SELL
$107.11 - $132.09 $145 Million - $178 Million
-1,351,133 Reduced 98.03%
27,176 $1.04 Million
Q1 2019

May 14, 2019

BUY
$62.15 - $129.99 $74.2 Million - $155 Million
1,194,634 Added 650.41%
1,378,309 $162 Million
Q4 2018

Feb 14, 2019

SELL
$55.16 - $69.67 $1.79 Million - $2.26 Million
-32,379 Reduced 14.99%
183,675 $11.5 Million
Q3 2018

Nov 14, 2018

SELL
$63.77 - $76.28 $22.4 Million - $26.8 Million
-351,169 Reduced 61.91%
216,054 $15.3 Million
Q2 2018

Aug 14, 2018

SELL
$58.55 - $73.92 $5.77 Million - $7.28 Million
-98,504 Reduced 14.8%
567,223 $37.7 Million
Q1 2018

May 15, 2018

BUY
$38.98 - $68.04 $5.26 Million - $9.18 Million
134,936 Added 25.42%
665,727 $43.5 Million
Q4 2017

Feb 14, 2018

BUY
$31.98 - $40.38 $587,696 - $742,063
18,377 Added 3.59%
530,791 $21.3 Million
Q3 2017

Nov 14, 2017

BUY
$26.89 - $37.1 $13.8 Million - $19 Million
512,414
512,414 $18.6 Million

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.24B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.